Background-Transplant vasculopathy is the main limiting factor of the long-term success of heart transplantation. We sought to establish the role of platelets in the development and progression of transplant vasculopathy. Methods and Results-Platelet analysis and intracoronary ultrasound examination were performed in 78 heart transplant recipients. Quantitative intracoronary ultrasound was used to define the severity of disease at baseline (48.8Ϯ4.5 months after transplantation) and at 1-year follow-up. 
T ransplant vasculopathy is the leading cause of late mortality and limits the long-term success of heart transplantation. [1] [2] [3] Transplant vasculopathy is a diffuse and progressive thickening of the arterial intima that develops in the major and minor coronary arteries of transplanted heart allografts. 2 The result is sudden and/or chronic progressive ischemic damage to the transplanted heart with subsequent functional organ failure. 4 Similar phenomena exist between ordinary atherosclerosis and transplant vasculopathy, which includes the presence of a concentration of subendothelial inflammatory cells (monocytes/macrophages, T-lymphocytes), intimal smooth muscle cell proliferation, and extracellular matrix reorganization. 5 Transplant vasculopathy is diffuse and frequently involves long segments of the affected arteries. It is characterized by concentric intimal thickening, 6 whereas ordinary atherosclerosis usually involves one part of the artery more heavily than other parts, the latter producing prominent eccentric lesions. 7 In the past, numerous pathomechanisms have been thought to be involved in the development of transplant vasculopathy, which includes immune-mediated vascular injury, inflammation of the vascular endothelium, ischemia-reperfusion injury, cytomegalovirus infection, or metabolic risk factors. 2 Although the role of platelets in the development of atherosclerosis has been well recognized, the pathophysiological alterations of platelets in the context of transplant vasculopathy have been poorly studied. Platelets contain a variety of proinflammatory and proliferative compounds that are released in the microenvironment of thrombus formation. 8 Contact of platelets with the endothelium induces alterations in the adhesive and chemotactic properties of the endothelial cells that support monocyte adhesion and transmigration and thereby the early inflammatory mechanisms in the process of atherosclerotic changes within the vessel wall. 9 -12 The purpose of this study was to evaluate the changes of platelet membrane glycoproteins as immunological activation markers of circulating platelets in patients with transplant vasculopathy.
Methods

Patients and Study Design
A total of 78 consecutive patients, who underwent routine clinical follow-up after allograft heart transplantation, were entered into the study. The indications for heart transplantation were terminal congestive heart failure caused by idiopathic cardiomyopathy (nϭ57), primary pulmonary hypertension (nϭ3), ischemic heart disease (nϭ17), and congenital valve disease (nϭ1). Patients were treated with standard triple-drug immunosuppressive therapy that consisted of cyclosporine, corticosteroids, and azathioprine. Prospectively, we hypothesized that changes in platelet membrane glycoproteins, which occur in patients with transplant vasculopathy, are associated with the severity and progression of the disease. All patients (nϭ78) were evaluated by heart catheterization, coronary angiography, and quantitative intracoronary ultrasound at the commencement of the study, and 71% of the patients (nϭ55) were reevaluated after 1 year. The time from transplant to initial enrollment of all patients was 48.8Ϯ4.5 months (meanϮSEM; range 12.3 to 56.3 months) ( Table 1) .
According to quantitative intracoronary ultrasound (ICUS), described below, 13 we divided the study patients in 2 groups: group 1, diffuse, circumferential plaque formation, and group 2, focal or polyfocal plaque formation located at isolated sites with noncircumferential changes.
Blood samples were taken from the femoral artery before cardiac catheterization. With the use of a multiple-syringe sampling technique, the first 2 mL of blood was discarded. Thereafter, 2.5 mL of blood collected in EDTA was used for the determination of blood count, PlA polymorphism, and cyclosporine plasma levels. For flow cytometric analysis, 0.5 mL of blood was collected into a polypropylene syringe that contained 1.0 mL of a fixative that contained methacrolein (CyfixII). 14 The study protocol was approved by the Institutional Ethics Committee, and all patients provided informed written consent.
Heart Catheterization and ICUS
After intracoronary administration of 0.2 mg nitroglycerin, an intravascular ultrasound catheter (Five-64, F/X Endosonics) was pushed into the left coronary artery, and catheter pullback was performed manually. For longitudinal orientation, septal or diagonal branches were used as anatomic landmarks. Qualitative and quantitative plaque analysis was done at the site of minimum lumen diameter for the left main coronary artery and for every left anterior descending (LAD) segment. Evaluation of plaque morphology was carried out following published guidelines on ICUS imaging. 15 Because the conventional Stanford classification 6 considers only the cross-sectional changes, we used the following classification, 13 which also takes into account the longitudinal distribution of the plaque. Axial plaque distribution was classified as (1) "circumferential" if intimal thickening or plaque burden involved the total cross section of the vessel (Figure 1 , top), and (2) as "noncircumferential" if Ն10% of the cross section was free of plaque burden or intimal thickening (Figure 1, bottom) .
Longitudinal plaque distribution was classified as focal if only 1 (focal) or more (polyfocal) discrete coronary lesions separated by nondiseased were found throughout the ICUS pullback (Figure 1 , bottom) and as diffuse if continuous plaque formation that involved at least 1 complete coronary segment occurred (Figure 1, top) . According to the guidelines of intravascular ultrasound, 15 average plaque thickness, maximum plaque thickness (MPT), average plaque area, maximum plaque area, average intimal index, and maximum intimal index were calculated. Differences in plaque thickness within 1 year (⌬MPTϭMPT 2 ϪMPT 1 ) were calculated from MPT determined at time of the commencement of the study (MPT 1 ) and at 1-year follow-up (MPT 2 ). Disease progression was defined as an increase of Ͼ0.3 mm of MPT after 1 year at a precise anatomic site ( Figure 2 ). 16 
Platelet Flow Cytometry and Analysis of PlA (GPIIIa) Polymorphism
Evaluation of surface expression of platelet membrane glycoproteins was performed with the use of specific monoclonal antibodies and 2-color whole-blood flow cytometry, as described in detail elsewhere. 9, 17, 18 Specific monoclonal antibody binding was expressed as relative mean particle immunofluorescence (fluorescin) (CD41, ligand-induced binding site 1 [LIBS-1], generously provided by Dr Mark Ginsberg, Scripps Clinic, La Jolla, Calif) 9, 19 or percentage of positive platelets (CD62P) of total platelet population and was used as a quantitative measurement of glycoprotein surface expression. Five thousand events were analyzed. MAb anti-CD-42 (clone SZ 2), anti-CD62P (clone CLB Thromb/6), and anti-CD41 (clone P2) were purchased from Immunotech. PlA genotypes were determined by allele-specific restriction enzyme analysis as described by Gawaz et al. 18 
Statistical Analysis
Results of flow cytometric parameters are reported as medians (interquartile range) unless otherwise indicated. Differences between the 2 study groups were evaluated by means of appropriate unpaired nonparametric tests (Mann-Whitney U test). A multiple logistic regression analysis that implemented an automatic stepwise selection algorithm for risk factor inclusion was performed to assess independent risk factors for transplant vasculopathy and the progression of the disease. A receiver operating characteristic (ROC) curve for predicting progression of transplant vasculopathy was determined with an automatic algorithm (SPSS, Windows, version 9.0).
Results
Patient Characteristics
Between November 1996 and February 1999, we consecutively investigated 78 adult heart transplant recipients who underwent cardiac catheterization and intravascular ultrasound as a routine follow-up examination after transplantation (Tables 1 and 2 ). There was no statistically significant difference between the 2 groups for minimum lumen diameter (in millimeters) and diffuse versus focal disease (left main coronary artery: 4.7Ϯ1.2 versus 4.3Ϯ1.3; proximal LAD: 3.2Ϯ0.9 versus 3.4Ϯ1.5; mid-LAD: 3Ϯ0.8 versus 3.2Ϯ1; Figure 1 . ICUS images of patient after heart transplantation with diffuse (top) and focal (bottom) plaque formation. Right panels show cross-sectional image; left panels show longitudinal reconstruction. Depicted are representative images of patient with (bottom) diffuse plaque formation of the LAD (homogeneous, noncalcified, circumferential plaque formation [3] with continuous plaque formation in entire LAD in longitudinal reconstruction) and (top) with focal plaque formation of LAD (noncircumferential, homogeneous plaque formation without calcification [3] with proximal location in longitudinal reconstruction of LAD [3] ). (7) has increased from 1.1. to 1.7 mm.
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distal LAD: 2.7Ϯ1 versus 2.8Ϯ1.1). According to published ICUS criteria, 13, 16 initially 43 patients had diffuse and 35 patients had focal transplant disease. At 1-year follow-up, paired intravascular ultrasound data were available for 55 (71%) of the 78 enrolled patients. The causes for dropout were death (nϭ1), acute myocardial infarction (nϭ1), refusal by the patient (nϭ12), and failure to attend the regular time interval of exactly 1 year Ϯ1 month after the first examination (nϭ8). Eight patients during the observation period of 1 year had a cardiac event, which included death (nϭ1), myocardial infarction (nϭ1), and coronary balloon angioplasty for progression of the disease (nϭ7).
Platelet Membrane Glycoproteins and Transplant Vasculopathy
At the time of enrollment, activated fibrinogen receptor on circulating platelets, as assessed by LIBS-1 immunoreactivity, was significantly increased in patients with diffuse disease when compared with those with focal transplant disease (Pϭ0.04) ( Table 3 and Figure 3) . Similarly, in the group of patients with diffuse transplant vasculopathy, degranulation of ␣-granula (P-selectin surface expression) was significantly enhanced (Pϭ0.04) ( Table 3 and Figure 3 ). No differences in surface density of GPIIb-IIIa (CD41) and GPIb (CD42) or platelet count were found between the 2 groups (Table 3) . Furthermore, distribution of the platelet polymorphic allele PlA2 (GPIIIa) was not significantly different in both groups (Table 3) .
LIBS-1 as Predictor of Diffuse Transplant Vasculopathy and Progression of Disease
Baseline patient and platelet variables were included in a logistic regression model to determine whether LIBS-1 is an independent variable that predicts the presence of diffuse transplant vasculopathy. As shown in Table 4 , platelet surface expression of LIBS-1 was independently associated with diffuse transplant vasculopathy. For patients with enhanced LIBS-1 immunoreactivity (Ͼ75% quartile), there was a 3.3-fold increased relative risk (95% CI 1.8 and 18.9, Pϭ0.002) of diffuse transplant vasculopathy when compared with patients with LIBS-1 values in the range Յ75% quartile. In 55 of the 78 enrolled patients, we were able to calculate changes in MPT from follow-up paired intravascular ultrasound data at 1 year (Table 2) . We found that LIBS-1 immunoreactivity correlated with plaque progression (increase of Ն0.3 mm in MPT after 1 year) (rϭ0.681, Pϭ0.002) To test whether LIBS-1 is associated with plaque progression independent of baseline patient and platelet variables, we performed a linear regression analysis that included the parameters given in Table 5 . Among the variables tested, only LIBS-1 immunoreactivity was associated independently with the progression of transplant vasculopathy. To predict progression for an individual heart transplant recipient by using the levels of LIBS-1 immunoreactivity, we calculated the ROC curve. The area under the ROC curve for the prediction of progression of transplant vasculopathy by LIBS-1 immunoreactivity was 0.811. The optimum cutoff value was 16.5 ( Figure 5 
Discussion
The major findings of this prospective study are as follows:
(1) diffuse transplant vasculopathy, as assessed by intracoronary ultrasound, is associated with enhanced fibrinogen receptor activation (LIBS-1 expression) and degranulation of ␣-granula (P-selectin surface expression) of the circulating platelets; (2) progression of MPT within 1 year correlates with the activation of the platelet fibrinogen receptor; and (3) LIBS-1 surface expression on circulating platelets is a predictor of the progression of transplant vasculopathy independent of demographic variables and conventional cardiovascular risk factors. These findings imply that enhanced activation of circulating platelets in patients with heart transplants might contribute to the development and progression of transplant vasculopathy. If the activation of platelets induces atherogenesis, effective antiplatelet strategies may be beneficial for the long-term success of heart transplantation. However, platelet activation could serve as a passive indicator of transplant vasculopathy.
Transplant Vasculopathy, Atherosclerosis, and Platelets
In this study, we found that diffuse transplant vasculopathy, as assessed by the ICUS technique, is associated with increased surface expression of platelet membrane glycoproteins, which indicates activation of circulating platelets. This observation is concordant with previous studies 20 that demonstrated an enhanced ADP-induced platelet aggregation in patients after orthotopic heart transplantation.
In the early days of transplantation, the formation of platelet microthrombi and injury of the endothelium, followed by intimal smooth muscle cell proliferation, were suspected to be the cause of accelerated coronary graft disease. 21 In our study, we found a significant association between the activated state (LIBS-1 immunoreactivity) of the platelet fibrinogen receptor GPIIb-IIIa, which plays a fundamental role in arterial thrombotic events, and platelet adhesion to the endothelium. [22] [23] [24] In multivariate logistic regression analysis, we revealed that the association of LIBS-1 immunoreactivity with diffuse transplant vasculopathy is independent of other cardiovascular and transplant vasculopathy risk factors, which include hypercholesterolemia, plasma fibrinogen, diabetes, or smoking.
We also found that platelet degranulation (surface expression of P-selectin) is enhanced in patients with diffuse transplant vasculopathy, which implies that systemic release of proinflammatory (eg, platelet factor 4) and proliferative (eg, platelet-derived growth factor) compounds from activated platelets occurred. Thus, an enhanced release of platelet-derived mediators, either locally or systemically, might contribute to the acceleration and progression of transplant vasculopathy.
Pathophysiological Considerations
Intravascular examination of 78 heart transplant recipients revealed 43 patients with diffuse concentric lesions and 35 with focal eccentric lesions. Kapadia et al 16 and Tuzcu et al, 13 who performed serial intravascular ultrasound imaging with early baseline examination, detected focal eccentric lesions within a few weeks of transplantation, whereas the diffuse concentric lesions were only seen in the long-term follow-up. The authors believe that the diffuse changes probably represent the "real" transplant vasculopathy and regard the focal changes as donor-transmitted conventional atherosclerosis. Thus, the strong association between platelet LIBS-1 immunoreactivity and diffuse vasculopathy suggests that activation of platelets plays a fundamental part in the pathophysiology of transplant vasculopathy. Platelets have an important role in the onset of thrombosis, particularly in acute coronary syndromes. 25, 26 Less clear is whether platelets contribute to the origin and progression of atherosclerosis over an extended period of time. 26 Functional alterations of endothelial cells are an essential feature of the initial lesion that leads to monocyte/macrophage and lymphocyte accumulation that marks the beginning of atherosclerosis. 26 In this context, platelets may become involved in the process as early as the endothelial cells start losing their unique and essential ability to inhibit thrombogenic processes. The platelet fibrinogen receptor GPIIb-IIIa has been shown to mediate platelet/endothelium adhesion, 23, 24 which indicates that vascular lesions are not necessarily required for platelet attachment to the vessel wall. Thus, enhanced intermediate platelet deposition in coronary arteries of the transplanted heart may contribute to the localized release of various growth factors and cytokines, which cause the migration of monocytes and lymphocytes and the proliferation of smooth muscle cells and are early mechanisms that determine the progression of atherosclerosis. 10, 11, 25, 26 Experimental data show that activated platelets are able to induce secretion of the monocyte chemoattractant protein-1, a central factor for the chemotaxis of monocytes to the vessel wall. 10, 11 Moreover, platelets induce enhanced surface expression of adhesion receptors such as intracellular adhesion molecule-1 on endothelium that mediate adhesion and transmigration of leukocytes. 26 
Study Limitations
Although we show in this study that platelet activation and transplant vasculopathy are strongly associated, we do not provide evidence that platelets are directly and actively involved in the pathophysiology of transplant vasculopathy. However, our findings show that LIBS-1 expression is a good predictor for the progression of transplant vasculopathy, which suggests a direct role of platelet activation in the disease. At present, we cannot provide conclusive data that address the cause of enhanced activation of circulating platelets in patients with transplant vasculopathy. Future serial ultrasound examination, combined with flow cytometric platelet evaluation, performed within weeks of transplantation, might contribute to the elucidation of this issue. Because cyclosporine has been shown to induce hyperresponsive platelets, [27] [28] [29] one might speculate that the long-term administration of cyclosporine contributes to enhanced systemic platelet activation. Moreover, cyclosporine has been described as damaging endothelial cells and reducing the generation of prostacyclin, a major antiplatelet and vasodilator compound, 30 in heart transplant recipients. In our study, we did not find a correlation between the observed LIBS-1 expression and the plasma cyclosporine level; thus, cyclosporine is unlikely to be the cause for the observed platelet activation in the patient group with the diffuse changes but might act synergistically with other hitherto unknown factors to stimulate platelet activation. We used MPT measured at specific anatomic sites to monitor the progression of lesions because this is the most commonly reported parameter in the literature. 16 Progression of plaque thickness measured at 1 site only does not represent the progression of the total plaque burden. For this purpose, serial ECG-gated plaque volume calculations of the target vessel are necessary. 30 
Therapeutic Implications
Although platelets are a good candidate for pharmacological intervention of platelet-mediated atherosclerosis, conventional antiplatelet strategies with a monotherapy of aspirin have been found to be ineffective in preventing experimental and clinical transplant vasculopathy. 31 Only limited data with other antiplatelet drugs, such as thienopyridines, are available to date. 32 Because platelets can be activated by multiple pathways, administration of a single antiplatelet drug does not substantially reduce platelet activation and degranulation, particularly when a variety of strong agonists might contribute to platelet activation in vivo. Thus, it is of interest whether a combination of antiplatelet drugs that target various platelet activation pathways (aspirin, clopidogrel, fibrinogen receptor antagonists) might be more effective in limiting platelet activation in heart transplant recipients. In this context, Candinas and coworkers 33 demonstrated that a specific and selective platelet GPIIb-IIIa antagonist was effective in prolonging cardiac xenograft survival in a small-animal model. Further clinical studies are needed to show whether effective antiplatelet strategies are beneficial and safe for the long-term clinical course of patients after heart transplantation.
